Details About Generic Salt ::  Colfosce

Main Medicine Class:: Lung surfactant   

(kahl-FOSE-uhr-ILL PAL-mih-TATE)

Exosurf Neonatal

Class: Lung surfactant

Drugs Class ::

 Action Replaces deficient endogenous pulmonary surfactant and reduces surface tension.

Indications for Drugs ::

 Indications Prevention of neonatal respiratory distress syndrome (RDS) in infants with birth weight of < 1350 g; treatment of established hyaline membrane disease at all gestational ages. Adult RDS.

Drug Dose ::

 Route/Dosage

NEONATES & INFANTS: Intratracheal Prevention 5 ml/kg/installation as soon as possible after birth; second and third doses: approximately 12–24 hr later to infants remaining on mechanical ventilation. Rescue: 5 ml/kg/installation at confirmation of RDS diagnosis; repeat 5 ml/kg 12 hr later (if infant remains on mechanical ventilation).

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Drug should be administered only by trained personnel in closely supervised setting. Pulmonary hemorrhage: Occurred more commonly in infants weighing < 700 g.

Drug Side Effects ::

 Adverse Reactions

CNS: Intraventricular hemorrhage. RESP: Oxygen desaturation; pulmonary hemorrhage, nosocomial pneumonia; apnea; mucous plugs.

Drug Mode of Action ::  

 Action Replaces deficient endogenous pulmonary surfactant and reduces surface tension.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Determine infant’s weight, because accuracy is important for dosing.
• Maintain continuous ECG and transcutaneous oxygen saturation monitoring during administration; arterial BP monitoring is desirable.
• Maintain continuous bedside monitoring for at least 30 min after administration.
• Perform frequent blood gas monitoring after administration to prevent hypocarbia and hyperoxia.
• If chest expansion improves significantly after administration, reduce peak ventilator inspiratory pressures immediately. Do not wait for blood gas confirmation.
• Do not suction for 2 hr after administration unless airway is obstructed. Be alert for possible mucous plugs. Replace ET tube immediately if suctioning is unsuccessful.
• Monitor heart rate, color, respirations (rate, quality), facial expression, endotracheal tube patency and oximeter during and after administration.
• Continually monitor oxygen and carbon dioxide levels and be prepared to adjust ventilator appropriately.

Drug Storage/Management ::

 Administration/Storage

• For intratracheal administration only.
• Reconstitute immediately before use, if possible, with Sterile Water for Injection. Do not use solutions that contain preservatives or buffers. Gently swirl or shake suspension before administration.
• Do not use suspensions if persistent large flakes or particles are present.
• Administer by installation into trachea via side port on special adapter of endotracheal tube without interrupting mechanical ventilation.
• Before administering, assure proper placement of ET tube. Recheck during and after administration. If suctioning is required, allow patient’s condition to stabilize before administering. Suctioning should be done before installation and then no less than 2 hr after administration.
• Store unreconstituted powder at room temperature in a dry place.

Drug Notes ::

 Patient/Family Education

• Explain use and benefits of medication and its possible side effects.
• Advise family of infant’s condition and offer frequent updates.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.